VERA

Vera Therapeutics, Inc. (VERA) Scenario Analysis Analysis (2026)

Invetso Score: 2/10 — Weak · Last Updated: 2026-08-01

Overall Score

Business Momentum

Revenue and profitability remain absent in TTM data, with zero margins across gross, operating, EBITDA, pretax, and net profit.

Return metrics are deeply negative, including ROA of -0.75, ROE of -0.84, and ROIC of -0.86, indicating continued operating losses.

Balance Sheet

Liquidity is very strong, with a current ratio of 10.9 and cash ratio of 1.01, supported by cash per share of 6.95.

Leverage remains modest, with debt-to-equity of 0.18 and debt-to-assets of 0.14, while net debt to EBITDA is near zero at -0.07.

Valuation

Traditional earnings and cash-flow valuation metrics are not supportive, with negative earnings yield (-0.19) and negative free cash flow yield (-0.16).

The stock still screens as expensive on book-based measures, with price-to-book at 5.17 and price-to-fair-value at 5.17.

Cash Flow

Operating cash flow and free cash flow are both negative on a TTM basis, with FCF of -339.1M and FCF per share of -4.72.

Cash conversion remains poor, with operating cash flow ratio at -7.01 and interest coverage at -36.93, indicating weak internal funding generation.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Vera Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →